Advanced Solid Tumors
Dragonfly Therapeutics Inc. is active in clinical research for advanced solid tumors, including unresectable, recurrent, and metastatic disease. Its studies focus on treatment-resistant cancers where new oncology approaches are needed.
- Solid tumor oncology
- Metastatic cancer
- Recurrent malignancies
The sponsor’s portfolio includes investigational work in patients with advanced disease across selected indications, with attention to tumor control and clinical activity.
Immuno-Oncology Combinations
Several trials examine combination cancer therapy using agents paired with nivolumab and other systemic treatments, reflecting interest in immune-based strategies for solid tumors.
- Immune checkpoint inhibition
- Combination therapy
- Antitumor immune activity
These studies explore how investigational therapies may work alongside established immunotherapy and other anticancer regimens in advanced malignancies.
Selected Indication Expansion
Dragonfly Therapeutics Inc. is also studying efficacy expansion cohorts in selected cancer indications, extending evaluation beyond initial advanced tumor populations.
- Tumor-specific expansion cohorts
- Objective response assessment
- Clinical activity in defined indications
This area of research centers on identifying cancer subtypes where investigational therapies may show measurable antitumor effects.
Novel Therapeutic Agents
The sponsor’s clinical program includes investigation of new therapeutic candidates in patients with advanced solid tumors, supporting development in experimental oncology.
- Investigational anticancer agents
- Monotherapy evaluation
- Systemic cancer treatment
Research activity spans multiple sites and countries, with ongoing studies aimed at defining the clinical role of emerging treatments in difficult-to-treat cancers.
